866-997-4948(US-Canada Toll Free)

Warts - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 81 Pages

Warts - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Warts Pipeline Review, H1 2017, provides an overview of the Warts (Infectious Disease) pipeline landscape.

Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Warts Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 15, 1, 6 and 3 respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Warts - Overview
Warts - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Warts - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Warts - Companies Involved in Therapeutics Development
3M Drug Delivery Systems
Aclaris Therapeutics Inc
Agilvax Inc
Aviragen Therapeutics Inc
Biogenomics Ltd
BioMAS Ltd
Cutanea Life Sciences Inc
Cytovation AS
Foamix Pharmaceuticals Ltd
G&E Herbal Biotechnology Co Ltd
Laboratories Ojer Pharma SL
LEO Pharma A/S
Nielsen Biosciences Inc
Novan Inc
Novartis AG
Promius Pharma LLC
RXi Pharmaceuticals Corp
Tamir Biotechnology Inc
Verrica Pharmaceuticals Inc
Zydus Cadila Healthcare Ltd
Warts - Drug Profiles
(digoxin + furosemide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
854-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Albicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AX-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTA-074 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-0602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CyPep-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DFD-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FIT-039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
furosemide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrogen peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ingenol mebutate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LFX-453 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omiganan pentahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
povidone iodine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranpirnase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Samcyprone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Warts - Dormant Projects
Warts - Discontinued Products
Warts - Product Development Milestones
Featured News & Press Releases
Nov 29, 2016: Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206
Aug 18, 2016: Aclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
Jul 30, 2016: Cytovation granted EU patent for its lead product, CyPep-1, for the treatment of cutaneous warts
Jul 21, 2016: RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology
May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206
Dec 21, 2015: RXi Pharmaceuticals Announces the Initiation of a Phase 2 Trial in Dermatology with Samcyprone for Cutaneous Warts
Dec 07, 2015: Aclaris Therapeutics Initiates Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
Oct 26, 2012: South Africa, first to grant IP protection in anti-warts
May 07, 2003: Henderson Morley: Signed Licensing Agreement
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Warts, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Warts - Pipeline by 3M Drug Delivery Systems, H1 2017
Warts - Pipeline by Aclaris Therapeutics Inc, H1 2017
Warts - Pipeline by Agilvax Inc, H1 2017
Warts - Pipeline by Aviragen Therapeutics Inc, H1 2017
Warts - Pipeline by Biogenomics Ltd, H1 2017
Warts - Pipeline by BioMAS Ltd, H1 2017
Warts - Pipeline by Cutanea Life Sciences Inc, H1 2017
Warts - Pipeline by Cytovation AS, H1 2017
Warts - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
Warts - Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017
Warts - Pipeline by Laboratories Ojer Pharma SL, H1 2017
Warts - Pipeline by LEO Pharma A/S, H1 2017
Warts - Pipeline by Nielsen Biosciences Inc, H1 2017
Warts - Pipeline by Novan Inc, H1 2017
Warts - Pipeline by Novartis AG, H1 2017
Warts - Pipeline by Promius Pharma LLC, H1 2017
Warts - Pipeline by RXi Pharmaceuticals Corp, H1 2017
Warts - Pipeline by Tamir Biotechnology Inc, H1 2017
Warts - Pipeline by Verrica Pharmaceuticals Inc, H1 2017
Warts - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Warts - Dormant Projects, H1 2017
Warts - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Warts, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *